troglitazone has been researched along with rosiglitazone in 235 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (9.79) | 18.2507 |
| 2000's | 153 (65.11) | 29.6817 |
| 2010's | 55 (23.40) | 24.3611 |
| 2020's | 4 (1.70) | 2.80 |
| Authors | Studies |
|---|---|
| Cantello, BC; Cawthorne, MA; Cottam, GP; Duff, PT; Haigh, D; Hindley, RM; Lister, CA; Smith, SA; Thurlby, PL | 1 |
| Buckle, DR; Cantello, BC; Chapman, H; Clapham, JC; Coyle, PJ; Haigh, D; Hindley, RM; Holder, JC; Kallender, H; Latter, AJ; Lawrie, KW; Mossakowska, D; Murphy, GJ; Roxbee Cox, L; Smith, SA; Young, PW | 1 |
| Bhushan, V; Chakrabarti, R; Jajoo, HK; Lohray, BB; Madhavan, GR; Mamidi, RN; Murali, N; Rajagopalan, R; Rajesh, BM; Rao, BP; Rao, KN; Reddy, AK; Reddy, PG; Subramaniam, S; Vikramadithyan, RK | 1 |
| Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM | 1 |
| Adkison, KK; Blanchard, SG; Henke, BR; Leesnitzer, LM; Mook, RA; Plunket, KD; Ray, JA; Roberson, C; Unwalla, R; Willson, TM | 1 |
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Ardecky, R; Broderick, CL; Brooks, DA; Dominianni, SJ; Etgen, GJ; Faul, MM; Karanewsky, DS; Kauffman, RF; McCarthy, JR; Montrose-Rafizadeh, C; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, J; Warshawsky, AM; Winneroski, LL | 1 |
| Andersen, AS; Brand, CL; Bury, PS; Fleckner, J; Jeppesen, L; Lehmann, SV; Mogensen, JP; Mortensen, SB; Panajotova, V; Pettersson, I; Polivka, Z; Rasmussen, HB; Sauerberg, P; Sindelar, K; Sturis, J; Svensson, LA; Wassermann, K; Wöldike, HF; Wulff, EM; Ynddal, L | 1 |
| Goto, A; Nakajima, M; Nezu, J; Nozawa, T; Sugiura, S; Tamai, I; Tsuji, A; Yokoi, T | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Ajamie, RT; Briere, DA; Brozinick, JT; Devanarayan, V; Hawkins, ED; Henry, JR; Li, Y; Misener, EA; Montrose-Rafizadeh, C; Warshawsky, AM; Wilken, B; Yumibe, NP; Zink, RW | 1 |
| Bhattarai, BR; Cho, H; Ham, SW; Han, IO; Hwang, JS; Kafle, B; Kang, JS; Khadka, D; Lee, SM; Park, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Carroll, RT; Darvesh, AS; Funk, MO; Geldenhuys, WJ; Van der Schyf, CJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Altieri, F; Azzariti, A; Cervoni, L; Crestani, M; Di Giovanni, C; Fracchiolla, G; Gilardi, F; Giudici, M; Guerrini, U; Laghezza, A; Lavecchia, A; Loiodice, F; Mitro, N; Montanari, R; Paradiso, A; Piemontese, L; Pochetti, G; Porcelli, L; Simone, GM; Tortorella, P | 1 |
| Aldeco, M; Binda, C; Edmondson, DE; Geldenhuys, WJ; Mattevi, A; Tortorici, M | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Dhangar, K; Jagtap, R; Karpoormath, R; Noolvi, M; Patel, H; Rane, RA; Shaikh, MS; Sonawane, Y; Surana, S; Thapliyal, N | 1 |
| Bahia, MS; Chadha, N; Kaur, M; Silakari, O | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Adams, WJ; Artman, GD; Colca, JR; Gadwood, RC; Kletzien, RF; Larsen, SD; Lee, PH; McDonald, WG; Parker, TT; Tanis, SP; Zeller, JB | 1 |
| Norman, BH | 1 |
| Chen, S; Chen, Y; Fu, L; Zhang, L | 1 |
| Aamir Javed, M; Ikram, M; Jadoon, R; Mahnashi, MH; Rashid, U; Sadiq, A; Saeed Jan, M; Shahid, M | 1 |
| Amri, EZ; Gaillard, D; Grimaldi, PA; Inadera, H; Staccini, L; Teboul, L | 1 |
| Adams, M; Chatterjee, VK; Digby, JE; Holder, JC; Lazar, MA; Montague, CT; O'Rahilly, S; Prins, JB; Sanders, L; Sewter, CP; Smith, SA | 1 |
| Akatsuka, H; Arakawa, K; Homma, K; Iijima, I; Inamasu, M; Kawanami, S; Matsumoto, M; Okumura, K; Ozeki, M; Saiga, Y; Watanabe, A; Yasuda, K | 1 |
| Buckingham, RE; Chattington, PD; Naderali, EK; Walker, AB; Williams, G | 1 |
| Seed, B | 1 |
| Auwerx, J; Briggs, M; Chen, I; Desreumaux, P; Fruchart, JC; Geboes, K; Heyman, R; Lefebvre, AM; Najib, J | 1 |
| Kern, PA; Ranganathan, S | 1 |
| Burris, TP; Cryan, E; Demarest, KT; Osborne, MC; Pelton, PD; Zhou, L | 1 |
| Aaronson, PI; Knock, GA; Mishra, SK | 1 |
| Fleck, E; Goetze, S; Gotlibowski, T; Hsueh, WA; Kawano, H; Law, RE; Xi, XP | 1 |
| Aaltonen, LA; de la Chapelle, A; Eng, C; Kum, JB; Mueller, E; Sarraf, P; Smith, WM; Spiegelman, BM; Wright, HM | 1 |
| Burris, TP; Demarest, KT; Pelton, PD; Zhou, L | 1 |
| Hull-Ryde, EA; Sigel, CS; Su, JL; Winegar, DA; Wisely, GB | 1 |
| Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N | 1 |
| Fujita, T; Fukumoto, S; Miyamoto, M; Okazaki, R; Takeuchi, Y; Tanaka, K; Toriumi, M | 1 |
| Aaronson, PI; Mishra, SK | 1 |
| Kuritzky, L; Quillen, DM; Samraj, GP | 1 |
| Nakajima, M; Shimada, N; Suzuki, M; Tane, K; Yamazaki, H; Yokoi, T | 1 |
| Kuzuya, T | 1 |
| Shimizu, N | 1 |
| Kalus, AM; Rubin, GL; Simpson, ER; Zhao, Y | 1 |
| Horikoshi, H; Yachi, M | 1 |
| Brown, MN | 1 |
| King, AB | 1 |
| Reddy, SS | 1 |
| Camp, HS; Frankowski, CL; Hong, YH; Leff, T; Li, O; Shen, X; Vanbogelen, R; Wise, SC | 1 |
| Hangai, M; He, S; Hinton, DR; Hsueh, WA; Ishibashi, T; Kim, S; Law, RE; Murata, T; Ryan, SJ; Xi, XP | 1 |
| de Abrew, K; Mylvaganam, S; Samarasekera, MS | 1 |
| Krische, D | 1 |
| Hisatome, I; Ogino, K; Shigemasa, C; Shimoyama, M; Uchida, K | 1 |
| Bailey, CJ; Krentz, AJ; Melander, A | 1 |
| Kitahara, M; Naitoh, T; Tsuruzoe, N | 1 |
| Chandraratna, RA; Fleck, E; Goetze, S; Graf, K; Hsueh, WA; Kim, S; Kintscher, U; Law, RE; Nagpal, S; Wakino, S | 1 |
| Hishinuma, T; Mizugaki, M; Yamazaki, T | 1 |
| Barbehenn, E; Lurie, P; Sasich, LD; Wolfe, SM | 1 |
| Asakawa, M; Komuro, I; Masuda, Y; Nagai, T; Oka, T; Saito, T; Takano, H; Toyozaki, T | 1 |
| Stiefelhagen, P | 1 |
| Filz, HP | 1 |
| Arioglu, E; Chao, L; Gavrilova, O; Marcus-Samuels, B; Mason, MM; Moitra, J; Reitman, ML; Vinson, C | 1 |
| Kimura, H; Momose, Y; Moriyama, S; Odaka, H; Sakamoto, J; Sawada, H; Sugiyama, Y | 1 |
| Chen, L; Cohen, SE; Kahn, CR | 1 |
| Henry, RR; Mudaliar, S | 1 |
| Albrektsen, T; Fleckner, J | 1 |
| Funk, WB; Lenhard, MJ | 1 |
| Lloyd, SJ; Thomas, ML | 1 |
| Berthold, HK; Gouni-Berthold, I; Ko, Y; Sachinidis, A; Seul, C; Vetter, H; Weber, AA | 1 |
| Collins, AR; Hsueh, WA; Kawano, Y; Nicholas, SB; Wakino, S | 1 |
| Collins, AR; Hsueh, WA; Jackson, S; Kintscher, U; Law, RE; Meehan, WP; Noh, G; Palinski, W; Wakino, S | 1 |
| Banerji, MA; Lebovitz, HE | 1 |
| Janka, HU | 1 |
| Hayashi, T; Hosoda, K; Inoue, G; Inoue, R; Masuzaki, H; Nakao, K; Nishimura, H; Ogawa, Y; Shintani, M; Yamamoto, Y; Yonemitsu, S | 1 |
| Endo, T; Haraguchi, K; Hershman, JM; Ohta, K; Onaya, T | 1 |
| Hata, Y; Hinton, DR; Hsueh, WA; Ishibashi, T; Kim, S; Law, RE; Murata, T | 1 |
| Arima, S; Ikeda, Y; Ito, S; Kudo, M; Sato, K; Sugawara, A; Takeuchi, K; Taniyama, Y; Uruno, A | 1 |
| Gale, EA | 2 |
| Abe, I; Eto, K; Fujishima, M; Nakamura, Y; Ohya, Y | 1 |
| Blicklé, JF | 1 |
| Berthold, HK; Gouni-Berthold, I; Sachinidis, A; Seul, C; Vetter, H; Weber, AA | 1 |
| Csermely, P; Jermendy, G | 1 |
| Atzpodien, E; Bedoucha, M; Boelsterli, UA | 1 |
| Blumberg, RS; Nakajima, A; Wada, K | 1 |
| Algenstaedt, P; Hamann, A | 1 |
| Jazet, IM; Meinders, AE | 1 |
| Hsueh, WA; Kim, S; Kintscher, U; Kuroki, T; Law, RE; Liu, Z; Ohba, M; Schönthal, AH; Wakino, S; Yin, F | 1 |
| Collins, AR; Fleck, E; Goetze, S; Hsueh, WA; Kaneshiro, K; Kim, S; Kintscher, U; Law, RE; Meehan, WP | 1 |
| Scheen, AJ | 1 |
| Hiraoka, S; Kitamura, S; Kiyohara, T; Matsuzawa, Y; Miyazaki, Y; Nagasawa, Y; Shinomura, Y; Takakura, R; Toyota, M | 1 |
| Brunmair, B; Fürnsinn, C; Gras, F; Nowotny, P; Roden, M; Vierhapper, H; Waldhäusl, W | 1 |
| Nakajima, M; Yamamoto, Y; Yamazaki, H; Yokoi, T | 1 |
| Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H | 1 |
| Khan, MA; St Peter, JV; Xue, JL | 1 |
| Chayama, K; Fujimoto, Y; Kawasaki, Y; Kuwada, Y; Sasaki, T; Tsuchida, A | 1 |
| Azar, R; Banner, B; Bird, S; Bonkovsky, HL; Szabo, G | 1 |
| Battarbee, H; Coates, G; Nissim, I; Welbourne, T | 1 |
| Füzesi, L; Krüger, U; Middel, P; Mössner, R; Neumann, C; Reich, K; Schinner, S; Schulz, U | 1 |
| Greenberg, AS; Mathys, JM; Rabbi, MF; Skolnik, PR | 1 |
| Yamanouchi, T | 1 |
| Fackett, A; Hayden, MJ; Hewitt, NJ; Li, AP; Lloyd, S; Sakai, Y; Silber, PM | 1 |
| Aburatani, H; Blumberg, RS; Kadowaki, T; Matsuhashi, N; Nagai, R; Nakajima, A; Saubermann, LJ; Terauchi, Y; Wada, K; Zhao, S | 1 |
| Kaplowitz, N; Lewis, JH; Watkins, PB | 1 |
| Fujisawa, N; Ishimine, S; Kadowaki, T; Kawamori, T; Matsuhashi, N; Nakagama, H; Nakajima, A; Ochiai, M; Osawa, E; Sekihara, H; Wada, K | 1 |
| Camirand, A; López-Solache, I; Marie, V; Silva, JE; Vignault, E | 1 |
| Bae, MA; Rhee, H; Song, BJ | 1 |
| Bugelski, P; Elcock, F; Hahn, L; Hart, T; McFarland, D; Morgan, DG; Narayanan, PK; Schwartz, L; Zhang, C | 1 |
| Ehrenborg, E; Hall, K; Hilding, A; Lewitt, MS; Skogsberg, J | 1 |
| Carter, L; Ciaraldi, TP; Henry, RR; Mudaliar, SR; Reehman, N; Wilmsen, HM | 1 |
| Moses, R | 1 |
| Bierhaus, A; Brodbeck, K; Häring, HU; Schleicher, ED; Weigert, C | 1 |
| Bruemmer, D; de Dios, ST; Dilley, RJ; Ivey, ME; Jennings, GL; Law, RE; Little, PJ | 1 |
| Burgermeister, E; Liscovitch, M; Tencer, L | 1 |
| Graham, M; Lindsey, C; McMurphy, J | 1 |
| Chandramouli, J; Tolman, KG | 1 |
| Berger, JP; Blaschke, F; Bruemmer, D; Fleck, E; Forman, BM; Law, RE; Liu, J; Sakai, T; Van Herle, AJ; Yin, F | 1 |
| Flight, IH; Lord, JM; Norman, RJ | 1 |
| Game, BA; Huang, Y; Lopes-Virella, MF; Xu, M | 1 |
| Evers, BM; Farrow, B; Hashimoto, K; Iwamura, T; O'Connor, KL | 1 |
| Narce, M; Poisson, JP | 1 |
| Tesz, G; Zawalich, KC; Zawalich, WS | 1 |
| Asnani, S; DeSouza, C; Fonseca, V; Gilling, L; Suwattee, P | 1 |
| Bode, C; Ernst, S; Leugers, A; Lohrmann, J; Nordt, TK; Sobel, BE; Zirlik, A | 1 |
| Naito, Y; Yoshikawa, T | 1 |
| Atkins, KB; Brosius, FC; Northcott, CA; Watts, SW | 1 |
| Katoh, M; Maniratanachote, R; Minami, K; Nakajima, M; Yokoi, T | 1 |
| Guo, YT; Leng, XS; Li, T; Lin, XH; Zhao, JM | 1 |
| Ahmad, H; Brown, RD; Fox, J; Gen, M; Greyson, C; Long, CS; Lu, L; Perlov, D; Schwartz, GG; Weiss, SO; Xu, Y; Zhu, P | 1 |
| Cluxton, RJ; Heaton, PC; Hsu, VD; Li, Z; Moomaw, CJ; Rodriguez, EM; Weiss, SR; Zuckerman, IH | 1 |
| Chen, J; Chen, Q; Jiang, H; Shen, J; Shen, X; Sun, T | 1 |
| Camacho, IE; De Strooper, B; Dominguez, D; Merchiers, P; Serneels, L; Spittaels, K | 1 |
| Bureau, F; Desmet, C; Fiévez, L; Gillet, L; Gosset, P; Lekeux, P; Mélotte, D; Rongvaux, A; Seumois, G; Staels, B; Vanderplasschen, A; Warzée, B | 1 |
| Fonseca, VA; Jawa, AA | 1 |
| Gao, J; Wang, MW; Wu, B | 1 |
| Guo, YT; Leng, XS; Li, T; Lin, XH; Zhao, JM; Zhu, JY | 1 |
| Boden, G; Cheung, P; Homko, C; Mozzoli, M; Nichols, C; Showe, LC | 1 |
| Borkan, SC; Matsuhashi, N; Nakajima, A; Ohnishi, S; Saubermann, LJ; Schaefer, KL; Takahashi, H; Turner, JR; Wada, K; Wolfe, MM | 1 |
| Haas, C; Häring, HU; Kaltenbach, S; Machicao, F; Staiger, H; Stumvoll, M; Weisser, M | 1 |
| Ackerman, WE; Kniss, DA; Rovin, BH; Zhang, XL | 1 |
| Brougham, L; Chan, K; Duczak, N; Elliot, M; Lim, HK; Patel, K | 1 |
| Fischer, SM; He, G; Lubet, RA; Muga, S; Thuillier, P | 1 |
| Artwohl, M; Baumgartner-Parzer, SM; Freudenthaler, A; Fürnsinn, C; Hölzenbein, T; Huttary, N; Waldhäusl, WK | 1 |
| Fröhlich, E; Machicao, F; Wahl, R | 1 |
| Moreno Sánchez, D | 1 |
| Freston, JW; Schlichting, CL; Slavin, DE | 1 |
| Bultemeier, NC; Hartung, DM; Haxby, DG; Touchette, DR | 1 |
| Duan, S; Liu, F; Liu, H; Liu, Y; Peng, Y; Wang, H | 1 |
| Baumelou, A; Buhaescu, I; Deray, G; Heurtier, A; Izzedine, H; Launay-Vacher, V | 1 |
| Digiovanni, J; Fischer, SM; He, G; Sung, YM | 1 |
| Coyle, AT; Kinsella, BT | 1 |
| Brunskill, NJ; Chana, RS | 1 |
| Jang, KY; Jang, YB; Kang, KP; Kim, DH; Kim, W; Lee, JE; Lee, S; Moon, SO; Park, SK; Sung, MJ | 1 |
| Nilsson, PM; Sarafidis, PA | 1 |
| Bakris, GL; Sarafidis, PA | 1 |
| Alvarez-Sanchez, R; Hartung, T; Montavon, F; Pähler, A | 1 |
| Blero, D; Bruyns, C; Caspers, L; De Graef, C; Driessens, G; Dulku, S; Gonzalez, NS; Willermain, F | 1 |
| Blann, E; Dial, S; Dragan, YP; Guo, L; Muskhelishvili, L; Schroth, G; Shi, L; Sun, Y; Zhang, L | 1 |
| Campbell, IW; Mariz, S | 1 |
| Hruz, PW; Rudnick, DA; Shikapwashya, O; Tu, S; Turmelle, YP; Yan, Q | 1 |
| Ahn, HS; Hahn, SJ; Jang, HJ; Jo, YH; Kim, MJ; Kim, MS; Kim, SE; Kim, SY; Rhie, DJ; Sung, KW; Yoon, SH | 1 |
| Moseley, RH; Snow, KL | 1 |
| Brandt, U; Brüne, B; Dröse, S; Soller, M; von Knethen, A | 1 |
| Chen, L; Chien, S; Fan, Y; Fu, Y; Guan, Y; Qin, X; Tian, J; Wang, N; Zhang, P; Zhu, Y | 1 |
| Binder, BR; Blüml, S; Bochkov, VN; Exner, M; Fürnkranz, A; Ikonomu, E; Kadl, A; Krönke, G; Leitinger, N; Sarembock, IJ | 1 |
| Caelles, C; Díaz-Delfín, J; Morales, M | 1 |
| Hampton, T | 1 |
| Ball, SG; Mughal, RS; O'Regan, DJ; Porter, KE; Turner, NA; Warburton, P | 1 |
| Giaginis, C; Theocharis, S; Tsantili-Kakoulidou, A | 1 |
| Baek, HA; Choi, HN; Chung, MJ; Jang, KY; Kim, KR; Lee, HJ; Moon, WS; Park, HS | 1 |
| Elasy, T; Stafford, JM | 1 |
| Chalasani, N; Khashab, M | 1 |
| Jang, SK; Kim, JH; Kim, WJ | 1 |
| Bachmann, M; Dissmann, JP; Frank, S; Geisslinger, G; Goren, I; Pfeilschifter, J; Sader, R; Schiefelbein, D; Schmidt, H; Seitz, O | 1 |
| Grönberg, G; Hansen, SH; Jurva, U; Madsen, KG; Olsen, J; Skonberg, C | 1 |
| Beaumont, KA; Boyle, GM; Cook, AL; Muscat, GE; Parsons, PG; Smit, DJ; Smith, AG; Sturm, RA; Thurber, AE | 1 |
| Bianchi, A; Jouzeau, JY; Koufany, M; Moulin, D; Netter, P; Sebillaud, S | 1 |
| Chan, LY; Guo, H; Lai, KN; Leung, JC; Xiao, J | 1 |
| Bonnans, C; Chanez, P; Godard, P; Gras, D; Urbach, V; Vachier, I | 1 |
| Deng, R; Kaimal, R; King, R; Song, X; Yan, B | 1 |
| Fantus, IG; Goldberg, HJ; Munk, S; Wang, H; Whiteside, C; Xia, L | 1 |
| Chopra, B; Georgopoulos, NT; Hinley, J; Nicholl, A; Oleksiewicz, MB; Southgate, J | 1 |
| Butura, A; Edling, Y; Ek, M; Ingelman-Sundberg, M; Sivertsson, LK | 1 |
| Julie, NL; Ledoux, SP; Rachek, LI; Wilson, GL; Yuzefovych, LV | 1 |
| Karpushev, AV; Levchenko, V; Pavlov, TS; Staruschenko, A; Vandewalle, A | 1 |
| Corl, BA; Lengi, AJ | 1 |
| Clark, J; Corinaldi, J; Hébert, RL; Jasmin, BJ; Miura, P; Nasrallah, R; Paris, G | 1 |
| Fuchimoto, J; Go, M; Himi, T; Kamekura, R; Koizumi, J; Kojima, T; Masaki, T; Murata, M; Ogasawara, N; Ohkuni, T; Sawada, N; Tanaka, S | 1 |
| Nguyen, T; Stricker, SA; Swiderek, L | 1 |
| Liao, X; Wang, Y; Wong, CW | 1 |
| Banerjee, A; Flynt, L; Ghosh, S; Mellema, M; Panettieri, RA; Shore, SA; Williams, E; Zhu, M | 1 |
| Dornfeld, K; Skildum, A; Wallace, K | 1 |
| Abdel-Mageed, AB; Akingbemi, B; Bartol, F; Braden, T; Dennis, J; Hazi, A; Judd, R; Mansour, M; Morrison, E; Napier, I; Schwartz, D | 1 |
| Al-Alem, L; Curry, TE; Kilgore, MW; Southard, RC | 1 |
| Claude, N; Guillouzo, A; Renaud, MP; Rogue, A; Spire, C | 1 |
| Andersen, OS; Ashrafuzzaman, M; Greathouse, DV; Greisen, P; Lum, K; Lundbæk, JA | 1 |
| Andersen, OS; Greathouse, DV; Hemmings, HC; Herold, KF; Rusinova, R; Sanford, RL | 1 |
| Amacher, DE; Boucher, GG; Francone, O; Kerlin, RL; Morton, D; Pettersen, JC; Pruimboom-Brees, IM; Will, Y | 1 |
| Aziz, AR; Deliard, S; Grant, SF; Zhao, J | 1 |
| Chan, DS; Chan, EC; Chui, WK; Ho, HK; Lee, CY; New, LS; Saha, S; Wong, W; Yap, CW | 1 |
| Cheng, YC; Chiang, MC; Lin, KH; Yen, CH | 1 |
| Bucolo, C; Drago, F; Salomone, S; Siarkos, I; Sinagra, T; Tamburella, A; Urso, V | 1 |
| Cai, Y; Chang, JR; Guan, YF; Jia, MZ; Peng, DQ; Qi, YF; Tang, CS; Wu, W; Yu, YR; Zhang, J; Zhou, YB | 1 |
| Gunness, P; Heinzle, E; Ingelman-Sundberg, M; Mueller, D; Noor, F; Shevchenko, V | 1 |
| Celinski, K; Dworzanski, T; Fornal, R; Korolczuk, A; Madro, A; Slomka, M | 1 |
| Cho, DH; Han, SH; Jo, I; Kwon, KJ; Lee, EJ; Park, JH; Shin, CY; Song, KH | 1 |
| Choi, YJ; Ham, SA; Hwang, JS; Kang, ES; Kang, KR; Kim, GH; Lee, JH; Lee, WJ; Paek, KS; Park, MH; Seo, HG; Yoo, T | 1 |
| Brzozowski, T; Celinski, K; Dworzanski, T; Fornal, R; Korolczuk, A; Madro, A; Slomka, M | 1 |
| Fröhlich, E; Wahl, R | 1 |
| Arnett, TR; Butters, OR; Patel, JJ | 1 |
| Hindman, HB; Huxlin, KR; Jeon, KI; Kulkarni, A; Phipps, RP; Sime, PJ; Woeller, CF | 1 |
| Furumura, M; Hashimoto, T; Karashima, T; Numata, S; Ohyama, B; Tanida, N; Teye, K; Yan, Y | 1 |
| Abete, P; Bellia, A; Cacciatore, F; Capuani, B; Dave, KR; De Marchis, ML; Della-Morte, D; Donadel, G; Dong, C; Ferroni, P; Fogliame, G; Guadagni, F; Lauro, D; Pacifici, F; Palmirotta, R; Pastore, D; Pileggi, A; Rehni, AK; Ricordi, C; Roselli, M; Rundek, T; Sbraccia, P | 1 |
| Aubry, M; Guillouzo, A; Hewitt, P; Jiang, X; Jossé, R; Kopp-Schneider, A; Savary, CC | 1 |
| Ding, RG; Fan, X; Hu, D; Li, ZJ; Liu, Y; Wang, QJ; Wu, CQ | 1 |
| Geng, B; He, J; Jiang, H; Kuang, J; Liu, Q; Mo, L; Xu, C; Xu, G | 1 |
| Huxlin, KR; Jeon, KI; Phipps, RP; Sime, PJ | 2 |
| Taub, M | 1 |
| Adams, LA; Bedwell, DW; Calvert, NA; Cassidy, KC; Cramer, JW; Mohutsky, MA; Moulton, RD; Rougée, LR; Ruterbories, KJ; Yumibe, NP; Zhou, X | 1 |
| Khetani, SR; McVay, M; Sunada, WY; Ware, BR | 1 |
| Allen, KM; Coughlan, KA; Mahmood, FN; Ruderman, NB; Saha, AK; Valentine, RJ | 1 |
| Hahm, KB; Hong, SP; Jung, Y; Kim, DH; Kim, G; Kim, JW; Koo, JB; Lee, KJ; Lee, KM; Nam, MO; Shin, SJ; Yoo, J; Yoo, JH | 1 |
| Bandhakavi, S; Chen, M; Dirven, H; Fitch, SE; Kincaid, B; Leenaars, CHC; Mehta, J; Pound, P; Ram, R; Tsaioun, K; Vist, GE; Wright, RA | 1 |
39 review(s) available for troglitazone and rosiglitazone
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antidiuretic Agents; Antineoplastic Agents; Antioxidants; Drug Design; Humans; Molecular Targeted Therapy; Structure-Activity Relationship; Thiazolidinediones | 2015 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution | 2020 |
Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.
Topics: Carcinoma, Hepatocellular; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Hepatocytes; Humans; Interferons; Liver Neoplasms; Nucleotides; Organic Anion Transporters, Sodium-Dependent; Symporters; Virus Internalization | 2022 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Drug Monitoring; Humans; Hypoglycemic Agents; Liver Function Tests; Patient Selection; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Failure; Troglitazone | 2000 |
[The development of thiazolidinedione drugs as anti-diabetic agents].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Proper usage of thiazolidinediones].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[PPAR gamma and thiozolidinedione derivatives as an antidiabetic drug for treating insuline resistance].
Topics: Animals; Chromans; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2000 |
The thiazolidinediones or "glitazones" a treatment option for type 2 diabetes mellitus.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Synergism; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2000 |
The glitazones: proceed with caution.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Evaluation; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Prognosis; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Troglitazone; Weight Gain | 2000 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2001 |
Insulin resistance and its treatment by thiazolidinediones.
Topics: Adipose Tissue; Binding Sites; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dimerization; Drug Interactions; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Muscle, Smooth; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Factors; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Glitazones. Profile of a new class of substances].
Topics: Albuminuria; Animals; Anticholesteremic Agents; Chromans; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Humans; Hypoglycemic Agents; Isoenzymes; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
Lessons from the glitazones: a story of drug development.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Europe; Humans; Hypoglycemic Agents; Liver Failure; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
[Thiazolidinediones: clinical data and perspectives].
Topics: Animals; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[Thiazolidinediones--a new class of oral antidiabetic drugs].
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Glitazone--a new class of drugs for the treatment of type 2 diabetes].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].
Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Hepatotoxicity with thiazolidinediones: is it a class effect?
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[Insulin sensitizer drugs--review].
Topics: Adipose Tissue; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Repaglinide in combination therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Piperidines; Postprandial Period; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
Hepatotoxicity of the thiazolidinediones.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemic Agents; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2003 |
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Effects of the thiazolidinediones on cardiovascular risk factors.
Topics: Cardiovascular Diseases; Chromans; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Troglitazone | 2002 |
Thiazolidinediones: a new class of drugs for the therapy of ischemia-reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents; Chromans; Humans; Ligands; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Reperfusion Injury; Rosiglitazone; Thiazolidinediones; Transcription Factors; Troglitazone | 2004 |
Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.
Topics: Angioplasty, Balloon, Coronary; Animals; Biguanides; Blood Pressure; Chromans; Diabetic Angiopathies; Endothelium, Vascular; Fibrinolysis; Humans; Hypoglycemic Agents; Metformin; Oxidative Stress; Postprandial Period; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Troglitazone | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
PPAR-gamma-agonists' renal effects.
Topics: Animals; Chromans; Diabetes Mellitus; Hemodynamics; Humans; Hypoglycemic Agents; Kidney; PPAR gamma; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
The effects of thiazolidinediones on blood pressure levels - a systematic review.
Topics: Blood Pressure; Chromans; Humans; Hypertension; MEDLINE; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone | 2006 |
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
Topics: Albuminuria; Animals; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin-1; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Troglitazone | 2006 |
Beta-cell preservation with thiazolidinediones.
Topics: Chromans; Diabetes Mellitus; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone | 2007 |
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Troglitazone | 2007 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Prognosis; Rosiglitazone; Thiazolidinediones; Troglitazone | 2007 |
[Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
Topics: Animals; Arthritis, Rheumatoid; Chromans; Dimerization; Extracellular Matrix; Humans; Hypoglycemic Agents; Joint Diseases; Osteoarthritis; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Troglitazone | 2008 |
The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Chromans; Female; Forecasting; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Iodine Radioisotopes; Male; Molecular Targeted Therapy; Pyrazoles; Pyrimidines; Risk Assessment; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Treatment Outcome; Troglitazone | 2014 |
Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus; Humans; Pharmacogenetics; Pioglitazone; Precision Medicine; Risk Factors; Rosiglitazone; Thiazolidinediones; Troglitazone | 2014 |
Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; Liver; Rosiglitazone; Troglitazone | 2021 |
4 trial(s) available for troglitazone and rosiglitazone
| Article | Year |
|---|---|
Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.
Topics: Adipose Tissue; Animals; Arteries; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 1998 |
A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
Topics: Body Weight; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2002 |
Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients.
Topics: Adipose Tissue; Biological Transport; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Female; Gene Expression; Humans; Hypoglycemic Agents; Male; Middle Aged; Oxidation-Reduction; Oxidative Phosphorylation; Rosiglitazone; Thiazolidinediones; Troglitazone; Up-Regulation | 2005 |
192 other study(ies) available for troglitazone and rosiglitazone
| Article | Year |
|---|---|
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hemoglobins; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Structure-Activity Relationship; Thiazoles | 1994 |
Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.
Topics: 3T3 Cells; Adipocytes; Animals; Benzoxazoles; Female; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Phenylpropionates; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors | 1998 |
Novel euglycemic and hypolipidemic agents. 1.
Topics: Animals; Blood Glucose; Drug Evaluation, Preclinical; Hypoglycemic Agents; Hypolipidemic Agents; Indoles; Male; Mice; Mice, Inbred C57BL; Rats; Rats, Wistar; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Tissue Distribution; Triglycerides | 1998 |
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine | 1998 |
Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.
Topics: Animals; Biological Availability; Humans; Indoles; Rats; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Transcription Factors | 1999 |
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
Topics: Animals; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Design; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Propionates; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Triglycerides | 2001 |
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
Topics: Animals; Blood Glucose; Carbazoles; Cholesterol; Cholesterol, Dietary; Crystallography, X-Ray; Drug Evaluation, Preclinical; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Molecular; Nuclear Proteins; Phenylpropionates; Pioglitazone; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2002 |
Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.
Topics: Biological Transport, Active; Chemical and Drug Induced Liver Injury; Chromans; Cloning, Molecular; DNA, Complementary; Estrone; Hepatocytes; Humans; Hypoglycemic Agents; Molecular Sequence Data; Oocytes; Organic Anion Transporters; Pioglitazone; Protein Binding; Quinones; Reverse Transcriptase Polymerase Chain Reaction; Thiazolidinediones; Troglitazone | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Topics: Animals; Blood Glucose; Humans; Hypoglycemic Agents; Mice; Models, Molecular; Peroxisome Proliferator-Activated Receptors; PPAR gamma; Rosiglitazone; Tetrahydroisoquinolines; Thiazolidinediones | 2006 |
Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects.
Topics: Animals; Anti-Obesity Agents; Binding Sites; Blood Glucose; Catalytic Domain; Computer Simulation; Enzyme Inhibitors; Hypoglycemic Agents; Mice; Phenyl Ethers; PPAR gamma; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Thiazolidinediones | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.
Topics: Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
Topics: Adipocytes; Animals; Antineoplastic Agents; Benzoxazoles; Body Weight; Calorimetry; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Partial Agonism; Drug Screening Assays, Antitumor; Fibric Acids; Fibroblasts; Gene Expression Profiling; Humans; Insulin Resistance; Intra-Abdominal Fat; Liver; Mice; Mice, Inbred C57BL; Models, Molecular; PPAR alpha; PPAR gamma; Propionates; Stereoisomerism; Structure-Activity Relationship; Urea | 2012 |
Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.
Topics: | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Structural insight of glitazone for hepato-toxicity: Resolving mystery by PASS.
Topics: Apoptosis; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Thiazolidinediones | 2015 |
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Insulin Resistance; Molecular Structure; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones | 2018 |
Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.
Topics: Hydrazones; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship; Thiazolidines | 2022 |
Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Actins; Adipose Tissue; Animals; Biomarkers; Carrier Proteins; Cell Differentiation; Cell Division; Chromans; Clone Cells; Creatine Kinase; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids, Nonesterified; Gene Expression; Glycerolphosphate Dehydrogenase; Hypoglycemic Agents; Linoleic Acid; Linoleic Acids; Mice; Muscles; Myelin P2 Protein; Myogenin; Neoplasm Proteins; Nerve Tissue Proteins; Palmitic Acid; Palmitic Acids; Phenotype; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.
Topics: Adipocytes; Animals; Cell Differentiation; Cells, Cultured; Chromans; Humans; Mice; Microbodies; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone | 1997 |
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Male; Mice; Obesity; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
PPAR--the good news and the bad.
Topics: Adenomatous Polyposis Coli; Animals; Chromans; Humans; Hypoglycemic Agents; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1998 |
PPARgamma and colorectal carcinoma: conflicts in a nuclear family.
Topics: Adenomatous Polyposis Coli; Animals; Chromans; Colorectal Neoplasms; Humans; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1998 |
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice.
Topics: Adenocarcinoma; Animals; beta Catenin; Chromans; Colorectal Neoplasms; Cyclooxygenase 2; Cytoskeletal Proteins; HT29 Cells; Humans; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Prostaglandin-Endoperoxide Synthases; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors; Troglitazone | 1998 |
Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes.
Topics: Adipocytes; Animals; Biological Transport; Cell Differentiation; CHO Cells; Chromans; Cricetinae; Enzyme Inhibitors; Gene Expression Regulation; Glucose; Insulin; Insulin Resistance; Lipids; Lipoprotein Lipase; Mice; Protein Biosynthesis; Rats; RNA, Messenger; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1998 |
A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
Topics: Adipocytes; Animals; Base Sequence; Carrier Proteins; Cells, Cultured; Chromans; Diabetes Mellitus; DNA Probes; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Female; Gene Expression Regulation; Genetic Techniques; Humans; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Molecular Sequence Data; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Tretinoin; Troglitazone; Tumor Suppressor Proteins | 1999 |
Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes.
Topics: Animals; Aorta, Thoracic; Chromans; Electric Stimulation; Hypoglycemic Agents; In Vitro Techniques; Ion Channels; Male; Membrane Potentials; Muscle, Smooth, Vascular; Potassium Channels; Pulmonary Artery; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells.
Topics: Animals; Aorta, Thoracic; Calcium-Calmodulin-Dependent Protein Kinases; Cell Movement; Cells, Cultured; Chemotactic Factors; Chromans; Cycloheximide; Dactinomycin; Enzyme Activation; Insulin-Like Growth Factor I; Ligands; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Prostaglandin D2; Protein Synthesis Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Thrombin; Transcription Factors; Troglitazone | 1999 |
Loss-of-function mutations in PPAR gamma associated with human colon cancer.
Topics: Amino Acid Substitution; Binding Sites; Chromans; Colorectal Neoplasms; Dimerization; DNA-Binding Proteins; Exons; Genes, Tumor Suppressor; Humans; Hydroxyeicosatetraenoic Acids; Ligands; Linoleic Acids; Linoleic Acids, Conjugated; Mutation; Prostaglandin D2; Protein Binding; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Response Elements; Retinoid X Receptors; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone | 1999 |
PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes.
Topics: Adipocytes; Carrier Proteins; Cell Differentiation; Cell Line; Cells, Cultured; Chromans; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Gene Expression; Humans; Kinetics; Monocytes; Myelin P2 Protein; Neoplasm Proteins; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Suppressor Proteins | 1999 |
Use of a PPAR gamma-specific monoclonal antibody to demonstrate thiazolidinediones induce PPAR gamma receptor expression in vitro.
Topics: Adipocytes; Alternative Splicing; Animals; Antibodies, Monoclonal; Antibody Specificity; Cell Differentiation; Cell Line; Chromans; Humans; Hybridomas; Hypoglycemic Agents; In Vitro Techniques; Mice; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Species Specificity; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1999 |
Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro.
Topics: Acid Phosphatase; Adipocytes; Animals; Bone Marrow Cells; Bone Resorption; Calcitriol; Cell Differentiation; Cells, Cultured; Chromans; Hypoglycemic Agents; Interleukin-11; Isoenzymes; Mice; Mice, Inbred ICR; Osteoclasts; Parathyroid Hormone; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tartrate-Resistant Acid Phosphatase; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1999 |
Differential block by troglitazone and rosiglitazone of glibenclamide-sensitive K(+) current in rat aorta myocytes.
Topics: Animals; Aorta, Thoracic; Chromans; Glyburide; Hypoglycemic Agents; In Vitro Techniques; Male; Membrane Potentials; Muscle, Smooth, Vascular; Potassium Channel Blockers; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.
Topics: Chromans; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Hypoglycemic Agents; In Vitro Techniques; Isoenzymes; Kinetics; Microsomes, Liver; Oxidation-Reduction; Pioglitazone; Recombinant Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Xenobiotics | 2000 |
Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.
Topics: Adipose Tissue; Animals; Aromatase; Aromatase Inhibitors; Binding, Competitive; Breast; Breast Neoplasms; Cell Line; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Estrogens; Female; Gene Expression Regulation, Enzymologic; Humans; Ligands; Promoter Regions, Genetic; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Stromal Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone | 2000 |
How should patients taking the discontinued diabetes drug troglitazone be managed?
Topics: Alanine Transaminase; Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
Topics: 3T3 Cells; Animals; Cell Line; Chromans; Electrophoresis, Gel, Two-Dimensional; Epithelial Cells; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kidney; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Troglitazone; Trypsin | 2000 |
Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization.
Topics: Animals; Blotting, Western; Cell Division; Cell Movement; Choroid; Choroidal Neovascularization; Chromans; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; Fluorescein Angiography; Humans; Injections; Laser Coagulation; Ligands; Lymphokines; Macaca fascicularis; Male; Pigment Epithelium of Eye; Rats; Rats, Inbred BN; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
All that glitters in glitazones.
Topics: Antiviral Agents; Chromans; Drug Approval; Drug Prescriptions; Europe; Guanidines; Humans; Hypoglycemic Agents; National Health Programs; Pyrans; Rosiglitazone; Sialic Acids; Sri Lanka; Thiazoles; Thiazolidinediones; Troglitazone; United Kingdom; United States; United States Food and Drug Administration; Zanamivir | 1999 |
Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts.
Topics: Animals; Chromans; Dose-Response Relationship, Drug; Hemodynamics; Hypoglycemic Agents; Indomethacin; Isoxazoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Perfusion; Pioglitazone; Prostaglandins; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E | 2000 |
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
The effect of activation of peroxisome proliferator-activated receptor gamma (PPARgamma) on human monocyte function: PPARgamma ligands do not inhibit tumor necrosis factor-alpha release in human monocytic cell line THP-1.
Topics: Antineoplastic Agents; Carcinogens; Cell Survival; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Ligands; Monocytes; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha | 2000 |
Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Cell Movement; Chemokine CCL2; Chemotaxis; Chromans; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Flavonoids; Humans; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinases; Monocytes; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2000 |
Troglitazone has a reducing effect on thromboxane production.
Topics: Arachidonic Acid; Blood Platelets; Chromans; Diabetes Mellitus, Type 2; Fibrinolytic Agents; Gas Chromatography-Mass Spectrometry; Humans; Leukemia, Erythroblastic, Acute; Rosiglitazone; Thiazoles; Thiazolidinediones; Thromboxane A2; Troglitazone; Tumor Cells, Cultured; Vitamin E | 2000 |
Information on thiazolidinediones.
Topics: Chromans; Drug Industry; Humans; Hypoglycemic Agents; Internet; Ligands; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2000 |
Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.
Topics: Animals; Cell Nucleus; Cells, Cultured; Chromans; Drug Interactions; Gemfibrozil; Hypoglycemic Agents; Lipopolysaccharides; Myocardium; NF-kappa B; Peroxisome Proliferators; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone; Tumor Necrosis Factor-alpha | 2000 |
[New development in diabetes therapy. 35th Annual Meeting of the German Diabetes Society, Munich, May 5-June 3, 2000].
Topics: Chromans; Diabetes Mellitus, Type 2; Germany; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Insulin sensitizer. A new therapy option for type 2 diabetic patients].
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.
Topics: Adipose Tissue; Animals; Blood Glucose; Chromans; Diabetes Mellitus, Lipoatrophic; Disease Models, Animal; Female; Hypoglycemic Agents; Insulin; Ligands; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Receptors, Cytoplasmic and Nuclear; Respiratory Function Tests; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Troglitazone | 2000 |
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.
Topics: Animals; Apolipoprotein A-I; Bezafibrate; Chlorocebus aethiops; Chromans; COS Cells; Fenofibrate; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kinetics; Pioglitazone; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection; Troglitazone; Tumor Cells, Cultured | 2000 |
Unraveling the mechanism of action of thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
The transcription factor Fos-related antigen 1 is induced by thiazolidinediones during differentiation of 3T3-L1 cells.
Topics: 3T3 Cells; Animals; Cell Differentiation; Cell Nucleus; Chromans; Dimerization; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypoglycemic Agents; Mice; Pioglitazone; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Receptors, Cytoplasmic and Nuclear; RNA Stability; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Troglitazone; Up-Regulation | 2001 |
Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Pulmonary edema associated with rosiglitazone and troglitazone.
Topics: Aged; Chromans; Diabetes Mellitus, Type 2; Humans; Male; Pulmonary Edema; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2001 |
Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway.
Topics: Animals; Apoptosis; Cells, Cultured; Chromans; Fibrinolytic Agents; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Rats; Rats, Inbred WKY; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.
Topics: Animals; Cell Nucleus; Cells, Cultured; Chromans; Cytoplasm; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; DNA; Dose-Response Relationship, Drug; Fibrinolysin; Glomerular Mesangium; Matrix Metalloproteinase Inhibitors; Plasminogen Activator Inhibitor 1; Platelet-Derived Growth Factor; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Arteriosclerosis; Blood Glucose; Body Weight; Cell Movement; Cells, Cultured; Chemokine CCL2; Chromans; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Endothelium, Vascular; Flavonoids; Fructose; Humans; Insulin; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Receptors, LDL; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Vasodilator Agents | 2001 |
Troglitazone induces GLUT4 translocation in L6 myotubes.
Topics: Animals; Biological Transport; Cell Line; Cell Membrane; Chromans; Cycloheximide; Deoxyglucose; Gene Expression Regulation; Glucose Transporter Type 1; Glucose Transporter Type 3; Glucose Transporter Type 4; Insulin; Kinetics; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Nerve Tissue Proteins; Protein Transport; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone | 2001 |
Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Northern; Carcinoma, Papillary; Cell Division; Chromans; Humans; Male; Mice; Mice, Inbred BALB C; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thymidine; Thyroid Neoplasms; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2001 |
Response of experimental retinal neovascularization to thiazolidinediones.
Topics: Animals; Blotting, Western; Cattle; Cell Division; Cell Movement; Chromans; Endothelial Growth Factors; Endothelium, Vascular; Fluorescein Angiography; Hypoglycemic Agents; Immunoenzyme Techniques; Injections; Lymphokines; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Models, Animal; Phosphorylation; Retinal Ganglion Cells; Retinal Neovascularization; Retinal Vessels; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.
Topics: alpha-Tocopherol; Animals; Cells, Cultured; Chromans; Gene Expression; Hypoglycemic Agents; Muscle, Smooth, Vascular; Pioglitazone; Promoter Regions, Genetic; Rats; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Receptors, Thromboxane; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone | 2001 |
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.
Topics: Analysis of Variance; Animals; Barium; Calcium; Chromans; Dose-Response Relationship, Drug; Electric Stimulation; Female; Guinea Pigs; Humans; Insulin Resistance; Ion Channels; Isoxazoles; Membrane Potentials; Muscle, Smooth, Vascular; Pioglitazone; Potassium Channels; Prostaglandin D2; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth.
Topics: Animals; Aorta, Thoracic; Blotting, Western; Cell Division; Chromans; DNA; Enzyme Activation; Hypoglycemic Agents; JNK Mitogen-Activated Protein Kinases; Kinetics; Lipoproteins, LDL; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Inbred WKY; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
Topics: Chromans; Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Liver; Liver Function Tests; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2000 |
Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus; Fatty Liver; Gene Expression; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Obesity; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Up-Regulation | 2001 |
PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease.
Topics: Animals; Anti-Inflammatory Agents; Chromans; Colitis, Ulcerative; Crohn Disease; Disease Models, Animal; Inflammation; Intestines; Ligands; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells.
Topics: Acetophenones; Adenoviridae; Animals; Aorta, Thoracic; Apoptosis; Benzopyrans; Blotting, Western; Carbazoles; Cell Division; Cells, Cultured; Chromans; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cycloheximide; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Hydroquinones; Indoles; Insulin; Isoenzymes; Kinetics; Ligands; Mice; Mitogens; Models, Biological; Muscle, Smooth, Vascular; Phosphorylation; Platelet-Derived Growth Factor; Precipitin Tests; Protein Kinase C; Protein Kinase C-delta; Protein Processing, Post-Translational; Protein Synthesis Inhibitors; Protein Tyrosine Phosphatases; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; RNA; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone; Tyrosine; Up-Regulation; Vanadates | 2001 |
Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration.
Topics: Animals; Aortic Diseases; Cell Adhesion; Cell Movement; Cell Nucleus; Cells, Cultured; Chromans; Cytosol; Enzyme Inhibitors; Graft Occlusion, Vascular; Ligands; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone | 2001 |
PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells.
Topics: Animals; Blotting, Northern; Blotting, Western; Cell Division; Cell Line; Cell Line, Transformed; Cell Nucleus; Chromans; Cyclin D1; DNA, Complementary; Dose-Response Relationship, Drug; Epidermal Growth Factor; Epithelial Cells; Flow Cytometry; Humans; Hypoglycemic Agents; Intestines; Ligands; Luciferases; Plasmids; Promoter Regions, Genetic; ras Proteins; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection; Troglitazone | 2001 |
Thiazolidinediones influence plasma steroids of male obese Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Glucose; Hormones; Insulin; Male; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Chromans; DNA Fragmentation; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured | 2001 |
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Cells, Cultured; Chromans; Disease Models, Animal; Gene Expression; Heart; Heterozygote; Hypoglycemic Agents; Ligands; Mice; Mice, Knockout; Myocardium; Organ Size; Pioglitazone; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer.
Topics: Antineoplastic Agents; Cell Division; Chromans; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Humans; Pancreatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2001 |
Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone.
Topics: Alkaline Phosphatase; Chemical and Drug Induced Liver Injury; Cholestasis; Chromans; Female; Humans; Hypoglycemic Agents; Liver Function Tests; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Transaminases; Troglitazone | 2002 |
Glitazones regulate glutamine metabolism by inducing a cellular acidosis in MDCK cells.
Topics: Acidosis; Alanine Transaminase; Animals; Cell Line; Chromans; Epithelial Cells; Glutamine; Hydrogen-Ion Concentration; Hypoglycemic Agents; Kidney; L-Lactate Dehydrogenase; Nitrogen; Nitrogen Isotopes; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Chromans; Dose-Response Relationship, Drug; Fibrinolytic Agents; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Melanoma; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Skin Neoplasms; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2002 |
Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cell Line; Chromans; Fenofibrate; HIV-1; Humans; Leukocytes, Mononuclear; Macrophages, Alveolar; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha; Virus Replication | 2002 |
Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors.
Topics: Adenosine Triphosphate; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Chemical and Drug Induced Liver Injury; Chromans; Coloring Agents; Female; Formazans; Glutathione; Hepatocytes; Humans; Hypoglycemic Agents; Infant; Liver Diseases; Male; Middle Aged; Neutral Red; Oxazines; Rosiglitazone; Sex Factors; Smoking; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Troglitazone; Xanthenes | 2002 |
[Meta-analysis shows: insulin sensitizer is safe for the liver].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.
Topics: Acute Disease; Animals; Antibody Formation; Antioxidants; Chromans; Colitis; Cytokines; Disease Models, Animal; Hypoglycemic Agents; Ligands; Mice; Mice, Inbred C57BL; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Th2 Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Did this drug cause my patient's hepatitis?
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Pioglitazone; Product Surveillance, Postmarketing; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.
Topics: Animals; Antineoplastic Agents; Azoxymethane; Carcinogens; Chromans; Colon; Colonic Neoplasms; Female; Immunohistochemistry; Ligands; Mice; Mice, Inbred BALB C; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Regulation of uncoupling protein-2 mRNA in L6 myotubules: I: Thiazolidinediones stimulate uncoupling protein-2 gene expression by a mechanism requiring ongoing protein synthesis and an active mitogen-activated protein kinase.
Topics: Animals; Cell Line; Chromans; Ion Channels; Membrane Transport Proteins; Mitochondrial Proteins; Mitogen-Activated Protein Kinases; Muscle Fibers, Skeletal; Proteins; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone; Uncoupling Protein 2 | 2002 |
Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Chromans; Cyclin A; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; G1 Phase; Humans; Liver Neoplasms; Protein Serine-Threonine Kinases; Rats; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2003 |
Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Membrane; Chromans; Coloring Agents; Dose-Response Relationship, Drug; Fibrinolytic Agents; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Glutathione; Membrane Potentials; Mitochondria; Models, Chemical; Oxidative Stress; Oxygen; Phenanthridines; Propidium; Rats; Rosiglitazone; Superoxides; Thiazolidinediones; Troglitazone | 2003 |
Troglitazone stimulates IGF-binding protein-1 by a PPAR gamma-independent mechanism.
Topics: Carcinoma, Hepatocellular; Chromans; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Protein 1; Kinetics; Liver Neoplasms; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone; Tumor Cells, Cultured | 2003 |
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.
Topics: Adult; CD36 Antigens; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Gene Expression; Humans; Insulin Resistance; Male; Membrane Glycoproteins; Middle Aged; Muscle, Skeletal; Organic Anion Transporters; Oxidation-Reduction; Palmitic Acid; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
c-Fos-driven transcriptional activation of transforming growth factor beta-1: inhibition of high glucose-induced promoter activity by thiazolidinediones.
Topics: Animals; Cells, Cultured; Chromans; Glucose; Hydrogen Peroxide; Mice; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Swine; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transforming Growth Factor beta; Transforming Growth Factor beta1; Troglitazone | 2003 |
Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation.
Topics: Becaplermin; Cell Count; Cell Cycle; Cell Division; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Insulin; Ligands; Mammary Arteries; Mitogens; Muscle, Smooth, Vascular; Phosphorylation; Pioglitazone; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Radial Artery; Receptors, Cytoplasmic and Nuclear; Retinoblastoma Protein; Rosiglitazone; Saphenous Vein; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells.
Topics: Adenocarcinoma; Antigens, Differentiation; Antigens, Neoplasm; Breast Neoplasms; Caveolin 1; Caveolin 2; Caveolins; Cell Differentiation; Cell Line; Chromans; Colonic Neoplasms; Dimerization; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Dominant; Humans; Kidney; Ligands; Macromolecular Substances; Membrane Microdomains; Neoplasm Proteins; Phenotype; Phenylacetates; Prostaglandin D2; Protein Structure, Tertiary; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; RNA, Neoplasm; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone; Tumor Cells, Cultured | 2003 |
A retrospective review of thiazolidinediones with development of a troglitazone conversion protocol.
Topics: Aged; Alanine Transaminase; Chromans; Clinical Protocols; Contraindications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Monitoring; Drug Utilization Review; Guideline Adherence; Humans; Hypoglycemic Agents; Male; Middle Aged; Practice Guidelines as Topic; Quality Assurance, Health Care; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Troglitazone; United States; United States Department of Veterans Affairs | 2003 |
Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Binding Sites; Blotting, Northern; Caspase Inhibitors; Cell Division; Cells, Cultured; Chromans; Cysteine Proteinase Inhibitors; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; GADD45 Proteins; Gene Expression Regulation; Host Cell Factor C1; Humans; Intracellular Signaling Peptides and Proteins; Luciferases; Muscle, Smooth, Vascular; Mutation; Octamer Transcription Factor-1; Promoter Regions, Genetic; Protein Binding; Proteins; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone | 2003 |
Regulation of MMP-1 expression in vascular endothelial cells by insulin sensitizing thiazolidinediones.
Topics: Cells, Cultured; Chromans; Cysteine; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Eukaryotic Initiation Factors; Humans; Hypoglycemic Agents; Immunoblotting; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Methionine; Pioglitazone; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Troglitazone; Umbilical Veins | 2003 |
Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator.
Topics: Chromans; Humans; Integrins; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; Pancreatic Neoplasms; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Tissue Plasminogen Activator; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2003 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |
Contrasting effects of nateglinide and rosiglitazone on insulin secretion and phospholipase C activation.
Topics: Androstadienes; Animals; Chromans; Cyclohexanes; Enzyme Activation; Glucose; Hypoglycemic Agents; Indicators and Reagents; Inositol Phosphates; Insulin; Insulin Secretion; Islets of Langerhans; Male; Nateglinide; Perfusion; Phenylalanine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone; Type C Phospholipases; Wortmannin | 2003 |
Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.
Topics: Adipocytes; Adipose Tissue; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Troglitazone | 2004 |
Effects of PPAR-gamma ligands on vascular smooth muscle marker expression in hypertensive and normal arteries.
Topics: Animals; Aorta; Arteries; Biomarkers; Blood Pressure; Carotid Arteries; Chromans; Deoxyglucose; Desoxycorticosterone; Glucose Transporter Type 4; Hypertension; Ligands; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Smooth, Vascular; PPAR gamma; Prostaglandin D2; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sodium Chloride; Thiazolidinediones; Troglitazone | 2005 |
Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines.
Topics: Amino Acid Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chromans; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation; Heat-Shock Proteins; Humans; Hypoglycemic Agents; Liver Neoplasms; Molecular Chaperones; Molecular Sequence Data; Protein Disulfide-Isomerases; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Transfection; Troglitazone | 2005 |
Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.
Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Chromans; Diethylnitrosamine; Gene Expression; Glutathione Transferase; Hypoglycemic Agents; Immunohistochemistry; Ligands; Liver Neoplasms; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Troglitazone | 2004 |
PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.
Topics: alpha-Tocopherol; Animals; Antioxidants; Chromans; Coronary Circulation; Cytokines; Energy Metabolism; Fatty Acids, Nonesterified; Female; Hypoglycemic Agents; Male; Myocardial Contraction; Myocardial Reperfusion Injury; Myocardium; PPAR gamma; RNA, Messenger; Rosiglitazone; Sus scrofa; Thiazolidinediones; Troglitazone; Ventricular Function, Left | 2005 |
Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program.
Topics: Chromans; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Drug Labeling; Drug Utilization Review; Evaluation Studies as Topic; Female; Humans; Liver; Liver Function Tests; Male; Medicaid; Middle Aged; Ohio; Pharmacoepidemiology; Practice Patterns, Physicians'; Rosiglitazone; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2005 |
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
Topics: alpha-Galactosidase; Anilides; Cells, Cultured; Chromans; CREB-Binding Protein; Drug Evaluation, Preclinical; Genes, Reporter; Indomethacin; Ligands; Nuclear Proteins; Oxazoles; Pioglitazone; PPAR gamma; Prostaglandin D2; Protein Binding; Rosiglitazone; Thiazolidinediones; Trans-Activators; Troglitazone; Two-Hybrid System Techniques; Tyrosine; Yeasts | 2004 |
Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide.
Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Anilides; Animals; Aspartic Acid Endopeptidases; Cell Line; Cell Line, Tumor; Cells, Cultured; Cerebral Cortex; Chromans; Culture Media, Conditioned; Endopeptidases; Humans; Kidney; Mice; Neuroblastoma; Neuroglia; Neurons; Peptide Fragments; Pioglitazone; PPAR gamma; Protein Processing, Post-Translational; Receptor, Notch1; Receptors, Cell Surface; Recombinant Fusion Proteins; Retinoid X Receptors; Rosiglitazone; Thiazolidinediones; Transcription Factors; Tretinoin; Troglitazone | 2004 |
Pro-inflammatory properties for thiazolidinediones.
Topics: Cell Line; Cell Line, Tumor; Cell Survival; Chromans; Cytokines; Drug Synergism; Epithelial Cells; Humans; Inflammation Mediators; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Development of a complex scintillation proximity assay for high-throughput screening of PPARgamma modulators.
Topics: Chromans; PPAR gamma; Protein Binding; Retinoid X Receptor alpha; Rosiglitazone; Scintillation Counting; Thiazolidinediones; Troglitazone | 2005 |
[Pexoxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats].
Topics: Animals; Antineoplastic Agents; Chromans; Diethylnitrosamine; Ligands; Liver Neoplasms, Experimental; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells.
Topics: Anilides; Anoikis; Benzamides; Carcinoma, Hepatocellular; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Cell Shape; Chromans; Extracellular Matrix; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin beta1; Liver Neoplasms; PPAR gamma; Protein-Tyrosine Kinases; Pyridines; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Adiponectin receptor gene expression in human skeletal muscle cells is not regulated by fibrates and thiazolidinediones.
Topics: Adult; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Fatty Acid Desaturases; Female; Fenofibrate; Gene Expression Regulation; Humans; Hypoglycemic Agents; Male; Muscle Fibers, Skeletal; Peroxisome Proliferators; PPAR gamma; Pyrimidines; Receptors, Adiponectin; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Statistics, Nonparametric; Stearoyl-CoA Desaturase; Thiazolidinediones; Troglitazone | 2005 |
Modulation of cytokine-induced cyclooxygenase 2 expression by PPARG ligands through NFkappaB signal disruption in human WISH and amnion cells.
Topics: Amnion; Cells, Cultured; Chromans; Cyclooxygenase 2; Epithelial Cells; Gene Expression Regulation; Humans; Membrane Proteins; NF-kappa B; PPAR gamma; Prostaglandin D2; Prostaglandin-Endoperoxide Synthases; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha | 2005 |
Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Topics: Aryl Hydrocarbon Hydroxylases; Automation; Chromans; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Enzyme Inhibitors; Enzyme Reactivators; Humans; In Vitro Techniques; Kinetics; Mass Spectrometry; Microsomes, Liver; Mixed Function Oxygenases; Pharmaceutical Preparations; Pioglitazone; Reproducibility of Results; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
The effect of PPARgamma ligands on UV- or chemically-induced carcinogenesis in mouse skin.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Carcinogens; Cell Proliferation; Cell Transformation, Neoplastic; Chromans; Diet; Female; Keratinocytes; Ligands; Mice; PPAR gamma; RNA, Messenger; Rosiglitazone; Skin Neoplasms; Tetradecanoylphorbol Acetate; Thiazolidinediones; Troglitazone; Ultraviolet Rays | 2005 |
Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells.
Topics: Aorta; Apoptosis; Blotting, Western; Caspases; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Chaperonin 60; Chromans; DNA-Binding Proteins; Dose-Response Relationship, Drug; E2F Transcription Factors; E2F1 Transcription Factor; Endothelium, Vascular; Enzyme Activation; Humans; Hypoglycemic Agents; Ligands; Microscopy, Phase-Contrast; Mitochondria; Pioglitazone; PPAR gamma; Prostaglandin D2; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rosiglitazone; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha; von Willebrand Factor | 2005 |
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.
Topics: Adenocarcinoma, Follicular; Animals; Annexin A5; Apoptosis; Cell Differentiation; Cell Line, Transformed; Cell Proliferation; Chromans; Pioglitazone; PPAR gamma; Radiation-Sensitizing Agents; Retinoid X Receptor alpha; RNA, Messenger; Rosiglitazone; Swine; Symporters; Thiazolidinediones; Thyroglobulin; Thyroid Gland; Thyroid Neoplasms; Troglitazone | 2005 |
Rating the severity of the medical consequences of drug-induced liver injury.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Data Collection; Humans; Hypoglycemic Agents; Liver; Liver Function Tests; Pioglitazone; Risk Assessment; Rosiglitazone; Surveys and Questionnaires; Thiazolidinediones; Troglitazone | 2005 |
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
Topics: Adult; Aged; Case-Control Studies; Chromans; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Male; Medicaid; Middle Aged; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Inhibitory effect of PPAR-gamma activator on IL-6 and mPGES protein expression in PBMC induced by homocysteine.
Topics: Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Homocysteine; Humans; Interleukin-6; Intramolecular Oxidoreductases; Kidney Failure, Chronic; Leukocytes, Mononuclear; Microsomes; PPAR gamma; Prostaglandin-E Synthases; Renal Dialysis; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Cell Growth Processes; Chromans; Enzyme Activation; Humans; Insulin-Like Growth Factor I; Keratinocytes; Mice; Mice, Transgenic; Multienzyme Complexes; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Rosiglitazone; Signal Transduction; Skin Neoplasms; Thiazolidinediones; TOR Serine-Threonine Kinases; Transfection; Troglitazone | 2006 |
Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells.
Topics: Cell Line; Cell Line, Tumor; Chromans; Genes, Reporter; Humans; Leukemia, Erythroblastic, Acute; Luciferases; PPAR gamma; Promoter Regions, Genetic; Prostaglandin D2; Protein Isoforms; Receptors, Thromboxane A2, Prostaglandin H2; Retinoid X Receptor alpha; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factor AP-1; Transcription, Genetic; Troglitazone | 2006 |
Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor gamma.
Topics: Albumins; Anilides; Animals; Cells, Cultured; Cholesterol; Chromans; Farnesol; Kidney Tubules, Proximal; Ligands; Mevalonic Acid; Opossums; Polyisoprenyl Phosphates; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone | 2006 |
Rosiglitazone ameliorates cisplatin-induced renal injury in mice.
Topics: Anilides; Animals; Apoptosis; C-Peptide; Cell Line; Chromans; Cisplatin; Drug Evaluation, Preclinical; Glioma; Humans; Hypoglycemic Agents; Inflammation; Insulin; Intercellular Adhesion Molecule-1; Kidney; Kidney Diseases; Kidney Function Tests; Kidney Tubules, Proximal; Macrophages; Male; Mice; Mice, Inbred C57BL; Monocytes; PPAR gamma; Prostaglandin D2; Protein Transport; Rosiglitazone; Thiazolidinediones; Transcription Factor RelA; Troglitazone; Tumor Necrosis Factor-alpha | 2006 |
Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry.
Topics: Animals; Chromans; Chromatography, Liquid; Glutathione; Humans; Hypoglycemic Agents; In Vitro Techniques; Isotope Labeling; Mass Spectrometry; Microsomes, Liver; Pioglitazone; Rats; Rosiglitazone; Thiazolidinediones; Troglitazone | 2006 |
15-Deoxy-12,14-prostaglandin J2 inhibits interferon gamma induced MHC class II but not class I expression on ARPE cells through a PPAR gamma independent mechanism.
Topics: Cell Line; Cells, Cultured; Chromans; Coculture Techniques; Dinoprost; Enzyme Inhibitors; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Histocompatibility Antigens Class I; HLA-D Antigens; Humans; Immunologic Factors; Intercellular Adhesion Molecule-1; Interferon Regulatory Factor-1; Interferon Regulatory Factor-2; Interferon-gamma; Nuclear Proteins; Phosphorylation; Pigment Epithelium of Eye; PPAR gamma; Prostaglandin D2; Rosiglitazone; STAT Transcription Factors; T-Lymphocytes; Thiazolidinediones; Trans-Activators; Troglitazone | 2006 |
Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Chromans; Cluster Analysis; Gene Expression Profiling; Gene Expression Regulation; Hepatocytes; Humans; Hypoglycemic Agents; Liver Neoplasms; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Troglitazone | 2006 |
Rosiglitazone inhibits mouse liver regeneration.
Topics: Animals; Chromans; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Gene Expression Regulation; Interleukin-6; Liver Regeneration; Male; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; S-Phase Kinase-Associated Proteins; Signal Transduction; STAT3 Transcription Factor; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha; Vasodilator Agents | 2006 |
Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone.
Topics: Animals; CHO Cells; Chromans; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Kv1.3 Potassium Channel; Membrane Potentials; Patch-Clamp Techniques; Rosiglitazone; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2007 |
Effect of thiazolidinediones on bile acid transport in rat liver.
Topics: Animals; Bile Acids and Salts; Bile Canaliculi; Biological Transport; Cell Membrane; Cholestasis, Intrahepatic; Chromans; Dose-Response Relationship, Drug; Hypoglycemic Agents; Liver; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Transport Vesicles; Troglitazone | 2007 |
Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells.
Topics: Adenosine Triphosphate; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Chromans; Humans; Jurkat Cells; Mitochondria; Necrosis; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Troglitazone | 2007 |
Laminar shear stress up-regulates the expression of stearoyl-CoA desaturase-1 in vascular endothelial cells.
Topics: Animals; Blotting, Northern; Blotting, Western; Celiac Artery; Cell Movement; Cells, Cultured; Chromans; Endothelial Cells; Gene Expression Regulation; Humans; Immunohistochemistry; PPAR gamma; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Stearoyl-CoA Desaturase; Stress, Mechanical; Thiazolidinediones; Troglitazone | 2007 |
Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors.
Topics: Anti-Inflammatory Agents; Cell Proliferation; Cells, Cultured; Chromans; Cyclooxygenase 2; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Induction; Enzyme Inhibitors; Fenofibrate; Heme Oxygenase-1; Humans; Membrane Proteins; Metalloporphyrins; Muscle, Smooth, Vascular; Mutation; Myocytes, Smooth Muscle; Polymorphism, Genetic; PPAR alpha; PPAR gamma; Promoter Regions, Genetic; Protoporphyrins; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Transcription, Genetic; Transfection; Troglitazone; Tumor Necrosis Factor-alpha | 2007 |
Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Topics: Adipocytes; Adipose Tissue; Animals; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Insulin-Secreting Cells; JNK Mitogen-Activated Protein Kinases; Liver; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone | 2007 |
Diabetes drugs tied to fractures in women.
Topics: Chromans; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone | 2007 |
Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones.
Topics: Analysis of Variance; Antibodies, Monoclonal; Cells, Cultured; Chromans; Coronary Disease; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1alpha; Interleukin-1beta; Interleukin-6; Interleukins; Myocytes, Cardiac; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Simvastatin; Stimulation, Chemical; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha | 2007 |
Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity.
Topics: Chromans; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Lipids; Membranes, Artificial; Octanols; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Troglitazone; Water | 2007 |
A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Topics: Anilides; Benzamides; Blotting, Western; Carcinoma, Hepatocellular; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Chromans; Colony-Forming Units Assay; Humans; Hypoglycemic Agents; Immunoenzyme Techniques; Ligands; Liver Neoplasms; Neoplasm Invasiveness; PPAR gamma; Pyridines; Rosiglitazone; Thiazolidinediones; Troglitazone; Vimentin | 2007 |
Anti-inflammatory lipid mediator 15d-PGJ2 inhibits translation through inactivation of eIF4A.
Topics: Anti-Inflammatory Agents; Arachidonic Acid; Arsenites; Chromans; Cyclopentanes; Cytoplasmic Granules; Dinoprostone; Emetine; Enzyme Inhibitors; Eukaryotic Initiation Factor-2; Eukaryotic Initiation Factor-4A; Gene Expression Regulation; HeLa Cells; Humans; Hypoglycemic Agents; Inflammation; Poly(A)-Binding Proteins; PPAR gamma; Prostaglandin D2; Prostaglandins A; Protein Biosynthesis; Protein Synthesis Inhibitors; Rosiglitazone; Signal Transduction; Sodium Compounds; T-Cell Intracellular Antigen-1; Thiazolidinediones; TNF Receptor-Associated Factor 2; Troglitazone; Tumor Necrosis Factor-alpha | 2007 |
Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated prote
Topics: Animals; Cell Survival; Cells, Cultured; Chromans; Diabetes Mellitus; Dose-Response Relationship, Drug; Enzyme Activation; Female; Immunohistochemistry; Keratinocytes; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; p38 Mitogen-Activated Protein Kinases; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Troglitazone; Vascular Endothelial Growth Factor A; Wound Healing | 2008 |
Electrochemical oxidation of troglitazone: identification and characterization of the major reactive metabolite in liver microsomes.
Topics: Acetylcysteine; Animals; Chromans; Electrochemistry; Humans; Magnetic Resonance Spectroscopy; Microsomes, Liver; Molecular Structure; Oxidation-Reduction; Pioglitazone; Rats; Rosiglitazone; Thiazolidinediones; Troglitazone | 2008 |
PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.
Topics: Animals; Antineoplastic Agents; beta Catenin; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Chlorocebus aethiops; Chromans; COS Cells; Halofenate; Humans; Melanoma; PPAR gamma; RNA, Messenger; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone; Wnt Proteins | 2009 |
Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy.
Topics: Cells, Cultured; Chromans; Epithelial Cells; Female; Glomerulonephritis, IGA; Humans; Inflammation; Kidney Tubules, Proximal; Male; PPAR gamma; Rosiglitazone; Thiazolidinediones; Troglitazone | 2009 |
Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor.
Topics: Adenocarcinoma; Anilides; Bronchi; Calcium Signaling; Cell Division; Cell Line, Transformed; Cell Line, Tumor; Chromans; Humans; Hypoglycemic Agents; Lung Neoplasms; PPAR gamma; Receptors, G-Protein-Coupled; Respiratory Mucosa; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Troglitazone | 2009 |
Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones.
Topics: Animals; Cell Line, Tumor; Chromans; Humans; Luciferases, Renilla; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone | 2009 |
Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells.
Topics: AMP-Activated Protein Kinases; Animals; Cells, Cultured; Chromans; Collagen Type IV; Dose-Response Relationship, Drug; Gene Expression Regulation; Glucose; Membranes; Mesangial Cells; NADPH Oxidases; Oxidative Stress; PPAR gamma; Protein Kinase C; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Response Elements; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transfection; Troglitazone; Vascular Endothelial Growth Factor A | 2009 |
Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.
Topics: Apoptosis; Calcium; Calcium Channels; Caspase 3; Caspase 9; Cell Division; Cells, Cultured; Chromans; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Membrane Potential, Mitochondrial; Oxazines; p38 Mitogen-Activated Protein Kinases; Peroxisome Proliferator-Activated Receptors; Phenoxyacetates; Phenylpropionates; Rosiglitazone; Thiazolidinediones; Troglitazone; Urothelium | 2009 |
Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model.
Topics: Cell Line; Cell Line, Tumor; Cell Survival; Chemokines; Chromans; Coculture Techniques; Cytokines; Cytotoxins; Gene Expression Regulation; Humans; Liver; Models, Biological; Monocytes; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Toxicity Tests; Troglitazone | 2009 |
Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes.
Topics: Adenosine Triphosphate; Apoptosis; Cells, Cultured; Chromans; DNA Damage; DNA, Mitochondrial; Enzyme-Linked Immunosorbent Assay; Hepatocytes; Humans; Hypoglycemic Agents; PPAR gamma; Rosiglitazone; Thiazolidinediones; Troglitazone | 2009 |
Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.
Topics: Anilides; Animals; Benzamides; Biological Transport; Cell Survival; CHO Cells; Chromans; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Epithelial Sodium Channels; Hypoglycemic Agents; Insulin; Membrane Potentials; Pioglitazone; PPAR gamma; Pyridines; Rosiglitazone; Sodium; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Troglitazone | 2009 |
Factors influencing the differentiation of bovine preadipocytes in vitro.
Topics: Acetates; Acetyl-CoA Carboxylase; Adipocytes; Adipose Tissue; Animals; Cattle; Cell Culture Techniques; Cell Differentiation; Chromans; Fat Emulsions, Intravenous; Fatty Acid-Binding Proteins; Glycerolphosphate Dehydrogenase; Linoleic Acids, Conjugated; Male; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Troglitazone | 2010 |
Thiazolidinediones alter growth and epithelial cell integrity, independent of PPAR-γ and MAPK activation, in mouse M1 cortical collecting duct cells.
Topics: Animals; Apoptosis; beta Catenin; Cadherins; Cell Proliferation; Chromans; Kidney Tubules, Collecting; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinase Kinases; Models, Animal; p38 Mitogen-Activated Protein Kinases; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiazolidines; Troglitazone | 2010 |
PPARgamma agonists upregulate the barrier function of tight junctions via a PKC pathway in human nasal epithelial cells.
Topics: Cells, Cultured; Chromans; Epithelial Cells; Gene Expression; Gene Expression Regulation; Humans; Nasal Mucosa; PPAR gamma; Protein Kinase C; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Tight Junctions; Troglitazone | 2010 |
Stimulators of AMP-activated kinase (AMPK) inhibit seawater- but not cAMP-induced oocyte maturation in a marine worm: Implications for interactions between cAMP and AMPK signaling.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Chromans; Cyclic AMP; Enzyme Activation; Female; Hypoglycemic Agents; Mice; Mitochondria; Oocytes; Plant Extracts; Proto-Oncogene Proteins c-akt; Ribonucleotides; Rosiglitazone; Seawater; Signal Transduction; Thiazolidinediones; Troglitazone | 2010 |
Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein.
Topics: Adenosine Triphosphate; Apoptosis; Carrier Proteins; Cell Survival; Chromans; Gene Expression Regulation; Heat-Shock Proteins; Hep G2 Cells; Humans; Hypoglycemic Agents; Mitochondria, Liver; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; Reactive Oxygen Species; RNA-Binding Proteins; Rosiglitazone; Thiazolidinediones; Transcription Factors; Troglitazone | 2010 |
Anti-inflammatory effects of thiazolidinediones in human airway smooth muscle cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Anilides; Anti-Inflammatory Agents; Antimetabolites; Asthma; Cells, Cultured; Chromans; Cytokines; Enzyme Activators; Enzyme Inhibitors; Gene Knockdown Techniques; Humans; Hypoglycemic Agents; Inflammation Mediators; Metformin; Myocytes, Smooth Muscle; PPAR gamma; Pyrazoles; Pyrimidines; Respiratory System; Ribonucleotides; Rosiglitazone; Thiazolidinediones; Troglitazone; Vidarabine | 2011 |
Therapy: The second time as farce: rosiglitazone and the regulators.
Topics: Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; Troglitazone | 2011 |
Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cells, Cultured; Chromans; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Estrogen Receptor Modulators; Female; Heat-Shock Proteins; Humans; Mitochondria; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; Reactive Oxygen Species; Receptors, Estrogen; Rosiglitazone; Thiazolidinediones; Transcription Factors; Troglitazone | 2011 |
Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Survival; Chromans; Enzyme-Linked Immunosorbent Assay; Fatty Acid Synthase, Type I; Humans; Hypoglycemic Agents; Male; Neoplasms, Hormone-Dependent; PPAR gamma; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Vasodilator Agents | 2011 |
Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromans; Female; Gene Expression; Humans; Ovarian Neoplasms; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Troglitazone | 2011 |
Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
Topics: Alkanesulfonates; Animals; Chromans; Gene Expression Profiling; Genes; Glycine; Hepatocytes; Humans; Male; Oligonucleotide Array Sequence Analysis; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Troglitazone | 2011 |
Linear rate-equilibrium relations arising from ion channel-bilayer energetic coupling.
Topics: Algorithms; Capsaicin; Chromans; Energy Transfer; Genistein; Gramicidin; Hydrophobic and Hydrophilic Interactions; Ion Channel Gating; Ion Channels; Kinetics; Lipid Bilayers; Membrane Lipids; Models, Chemical; Octoxynol; Phosphatidylcholines; Protein Folding; Rosiglitazone; Thiazolidinediones; Troglitazone | 2011 |
Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery.
Topics: Animals; Cell Line; Cell Membrane; Chromans; Drug Discovery; Gramicidin; Insulin; Ion Channels; Lipid Bilayers; Membrane Potentials; Membrane Proteins; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Sodium Channels; Thiazolidinediones; Troglitazone | 2011 |
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; DNA Damage; Glycine; Hypoglycemic Agents; Ion Channels; Mice; Mitochondria; Mitochondrial Proteins; Oxazoles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; PPAR gamma; Rats; RNA-Binding Proteins; Rodentia; Rosiglitazone; Sarcoma; Thermogenesis; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 1 | 2012 |
Expression analyses of the genes harbored by the type 2 diabetes and pediatric BMI associated locus on 10q23.
Topics: Adipocytes; Adipogenesis; Arrhythmias, Cardiac; Body Mass Index; Cell Line; Chromans; Chromosomes, Human, Pair 10; Diabetes Mellitus, Type 2; Gene Expression Profiling; Genetic Diseases, X-Linked; Genetic Loci; Genetic Predisposition to Disease; Gigantism; Heart Defects, Congenital; Homeodomain Proteins; Humans; Hypoglycemic Agents; Insulin Resistance; Insulysin; Intellectual Disability; Kinesins; Linkage Disequilibrium; Rosiglitazone; Thiazolidinediones; Transcription Factors; Troglitazone | 2012 |
Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Biotransformation; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Dose-Response Relationship, Drug; Drug Design; Fatty Acid-Binding Proteins; Gene Expression Regulation; Glutathione; Humans; Hypoglycemic Agents; Liver Neoplasms; Mice; Microsomes, Liver; Molecular Structure; Phosphorylation; Pioglitazone; PPAR gamma; Protein Carbonylation; Receptor Protein-Tyrosine Kinases; Receptors, Peptide; Rosiglitazone; Structure-Activity Relationship; Succinimides; Thiazolidinediones; Troglitazone | 2012 |
PPARγ regulates the mitochondrial dysfunction in human neural stem cells with tumor necrosis factor alpha.
Topics: Adenosine Triphosphate; Adenylate Kinase; Caspase 3; Cell Survival; Chromans; Humans; Mitochondria; Neural Stem Cells; Oxidative Stress; Pioglitazone; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Signal Transduction; Sirtuin 1; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha; Up-Regulation | 2013 |
Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells.
Topics: Anilides; Animals; Chromans; Dose-Response Relationship, Drug; Enzyme Inhibitors; Femoral Artery; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitroarginine; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pioglitazone; PPAR gamma; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Troglitazone; Vasoconstriction | 2013 |
Peroxisome proliferator-activated receptor γ ligands retard cultured vascular smooth muscle cells calcification induced by high glucose.
Topics: Anilides; Animals; Biomarkers; Calcinosis; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Gene Expression Regulation; Glucose; Ligands; Male; Muscle, Smooth, Vascular; Osteoblasts; Phenotype; PPAR gamma; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Troglitazone; Vasoconstriction | 2013 |
3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies.
Topics: Acetaminophen; Albumins; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Cell Culture Techniques; Cell Line, Tumor; Chromans; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Hepatocytes; High-Throughput Screening Assays; Humans; Liver; Multidrug Resistance-Associated Protein 2; Rosiglitazone; Spheroids, Cellular; Thiazolidinediones; Toxicity Tests, Acute; Troglitazone; Urea | 2013 |
Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis.
Topics: Animals; Anti-Inflammatory Agents; Chromans; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gastrointestinal Agents; Inflammation Mediators; Interleukin-10; Interleukin-2; Interleukin-4; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Troglitazone | 2012 |
Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons.
Topics: Animals; Blotting, Western; Cells, Cultured; Cerebral Cortex; Chromans; Cyclin-Dependent Kinase 5; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Immunoprecipitation; Neurons; Phosphorylation; Pioglitazone; PPAR gamma; Protein Phosphatase 2; Rats; Rats, Sprague-Dawley; Rosiglitazone; tau Proteins; Thiazolidinediones; Transfection; Troglitazone | 2013 |
15-Deoxy-Δ(12,14)-prostaglandin J2 prevents oxidative injury by upregulating the expression of aldose reductase in vascular smooth muscle cells.
Topics: Aldehyde Reductase; Animals; Antioxidant Response Elements; Base Sequence; Cells, Cultured; Chromans; Enzyme Induction; Glucose Oxidase; Male; Mice; Molecular Sequence Data; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-E2-Related Factor 2; Oxidative Stress; Phosphatidylinositol 3-Kinases; Prostaglandin D2; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone; Up-Regulation | 2014 |
Comparison of anti-inflammatory properties of peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone in prophylactic treatment of experimental colitis.
Topics: Animals; Anti-Inflammatory Agents; Chromans; Colitis; Colon; Cytokines; Dextran Sulfate; Intestinal Mucosa; Male; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Troglitazone | 2013 |
PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity.
Topics: Adipogenesis; Animals; Cell Differentiation; Cells, Cultured; Chromans; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Droplets; Metformin; Mice; Osteoblasts; Osteoclasts; Osteogenesis; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Troglitazone | 2014 |
Inhibitory effects of PPARγ ligands on TGF-β1-induced corneal myofibroblast transformation.
Topics: Actins; Animals; Cats; Cell Line, Transformed; Cell Nucleus; Chromans; Collagen Type I; Cornea; Fibronectins; Fibrosis; Humans; Ligands; Myofibroblasts; p38 Mitogen-Activated Protein Kinases; Phosphorylation; PPAR gamma; Prostaglandin D2; Protein Kinase Inhibitors; Protein Transport; Rosiglitazone; Signal Transduction; Smad Proteins; Thiazolidinediones; Transforming Growth Factor beta1; Troglitazone; Wound Healing | 2014 |
Various peroxisome proliferator-activated receptor (PPAR)-γ agonists differently induce differentiation of cultured human keratinocytes.
Topics: Anti-Inflammatory Agents; Benzimidazoles; Benzoates; Cell Differentiation; Cells, Cultured; Chromans; Filaggrin Proteins; Gene Expression Regulation; Humans; Intermediate Filament Proteins; Keratinocytes; Membrane Proteins; Microscopy, Fluorescence; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; Skin; Telmisartan; Thiazolidinediones; Troglitazone | 2015 |
Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period.
Topics: Cell Line; Chromans; Drug Administration Schedule; Fenofibrate; Gene Expression Regulation; Hepatocytes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Microarray Analysis; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones; Transcriptome; Troglitazone | 2015 |
Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondria.
Topics: Cell Line, Tumor; Chromans; DNA, Mitochondrial; Electron Transport; Humans; Hypoglycemic Agents; Liver; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; Pioglitazone; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Troglitazone | 2015 |
Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance.
Topics: Adipocytes; Adipose Tissue; Animals; Chromans; Cyclic AMP; Dexamethasone; Diabetes Mellitus; Fatty Acids, Nonesterified; Glucocorticoids; Hydrolysis; Hypoglycemic Agents; Insulin Resistance; Lipolysis; Phosphorylation; Pioglitazone; Proto-Oncogene Proteins c-akt; Rats; Rosiglitazone; Signal Transduction; Thiazolidinediones; Triglycerides; Troglitazone | 2015 |
Inhibitory effects of PPARγ ligands on TGF-β1-induced CTGF expression in cat corneal fibroblasts.
Topics: Actins; Animals; Blotting, Western; Cats; Cells, Cultured; Chromans; Collagen Type I; Connective Tissue Growth Factor; Corneal Keratocytes; Fibronectins; Hypoglycemic Agents; JNK Mitogen-Activated Protein Kinases; Ligands; p38 Mitogen-Activated Protein Kinases; PPAR gamma; Prostaglandin D2; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1; Troglitazone | 2015 |
Cancer drug troglitazone stimulates the growth and response of renal cells to hypoxia inducible factors.
Topics: Antineoplastic Agents; Cell Hypoxia; Cell Proliferation; Cell Survival; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Humans; Hypoxia-Inducible Factor 1; Kidney Tubules, Proximal; PPAR gamma; Rosiglitazone; Thiazolidinediones; Troglitazone | 2016 |
Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats.
Topics: Administration, Intravenous; Animals; Biotransformation; Canagliflozin; Chromans; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Glucuronosyltransferase; Glyburide; Hepatocytes; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Rats, Sprague-Dawley; Rats, Zucker; Rosiglitazone; Species Specificity; Substrate Specificity; Sulfotransferases; Thiazolidinediones; Troglitazone | 2016 |
Exploring Chronic Drug Effects on Microengineered Human Liver Cultures Using Global Gene Expression Profiling.
Topics: 3T3 Cells; Animals; Cells, Cultured; Chemical and Drug Induced Liver Injury; Chromans; Coculture Techniques; Dose-Response Relationship, Drug; Fibroblasts; Gene Expression Profiling; Hepatocytes; Humans; Liver; Mice; Oxidative Stress; Primary Cell Culture; Rosiglitazone; Thiazolidinediones; Toxicogenetics; Transcriptome; Troglitazone | 2017 |
The effects of troglitazone on AMPK in HepG2 cells.
Topics: AMP-Activated Protein Kinases; Chromans; Diabetes Mellitus, Type 2; Enzyme Activation; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin; Phosphorylation; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone | 2017 |
Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts.
Topics: Actins; Cells, Cultured; Chromans; Extracellular Matrix Proteins; Fibrosis; Gene Expression; Humans; Intestines; Myofibroblasts; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-akt; Rosiglitazone; Smad2 Protein; Thiazolidinediones; Transforming Growth Factor beta1; Troglitazone | 2017 |
Antifibrotic Actions of Peroxisome Proliferator-Activated Receptor γ Ligands in Corneal Fibroblasts Are Mediated by β-Catenin-Regulated Pathways.
Topics: Actins; Animals; beta Catenin; Cats; Chromans; Collagen Type I; Cornea; Fibroblasts; Fibronectins; Fibrosis; Glycogen Synthase Kinase 3 beta; Lithium Chloride; p38 Mitogen-Activated Protein Kinases; Phosphorylation; PPAR gamma; Prostaglandin D2; Pyrvinium Compounds; Receptors, Transforming Growth Factor beta; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transforming Growth Factor beta1; Troglitazone | 2017 |